Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy uniQure N-V stock | $29.36

Learn how to easily invest in uniQure N-V stock.

uniQure N.V is a biotechnology business based in the US. uniQure N-V shares (QURE) are listed on the NASDAQ and all prices are listed in US Dollars. uniQure N-V employs 332 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in uniQure N-V

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – QURE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

uniQure N-V stock price (NASDAQ: QURE)

Use our graph to track the performance of QURE stocks over time.

uniQure N-V shares at a glance

Information last updated 2021-10-24.
Latest market close$29.36
52-week range$25.80 - $52.19
50-day moving average $32.79
200-day moving average $31.70
Wall St. target price$66.09
PE ratio 4.2797
Dividend yield N/A (0%)
Earnings per share (TTM) $6.65

Buy uniQure N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy uniQure N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

uniQure N-V price performance over time

Historical closes compared with the close of $29.36 from 2021-10-25

1 week (2021-10-19) 2.91%
1 month (2021-09-24) -13.06%
3 months (2021-07-26) 8.70%
6 months (2021-04-26) -15.99%
1 year (2020-10-26) -32.43%
2 years (2019-10-25) -40.60%
3 years (2018-10-26) 13.67%
5 years (2016-10-26) 320.63%

Is uniQure N-V under- or over-valued?

Valuing uniQure N-V stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of uniQure N-V's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

uniQure N-V's P/E ratio

uniQure N-V's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, uniQure N-V shares trade at around 4x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

uniQure N-V's EBITDA

uniQure N-V's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $307.3 million.

The EBITDA is a measure of a uniQure N-V's overall financial performance and is widely used to measure a its profitability.

uniQure N-V financials

Revenue TTM $500.2 million
Operating margin TTM 59.28%
Gross profit TTM $-84,886,000
Return on assets TTM 31.69%
Return on equity TTM 67.5%
Profit margin 60.66%
Book value $13.76
Market capitalisation $1.3 billion

TTM: trailing 12 months

Shorting uniQure N-V shares

There are currently 2.9 million uniQure N-V shares held short by investors – that's known as uniQure N-V's "short interest". This figure is 43.7% up from 2.0 million last month.

There are a few different ways that this level of interest in shorting uniQure N-V shares can be evaluated.

uniQure N-V's "short interest ratio" (SIR)

uniQure N-V's "short interest ratio" (SIR) is the quantity of uniQure N-V shares currently shorted divided by the average quantity of uniQure N-V shares traded daily (recently around 1.0 million). uniQure N-V's SIR currently stands at 2.81. In other words for every 100,000 uniQure N-V shares traded daily on the market, roughly 2810 shares are currently held short.

However uniQure N-V's short interest can also be evaluated against the total number of uniQure N-V shares, or, against the total number of tradable uniQure N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case uniQure N-V's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 uniQure N-V shares in existence, roughly 60 shares are currently held short) or 0.0625% of the tradable shares (for every 100,000 tradable uniQure N-V shares, roughly 63 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against uniQure N-V.

Find out more about how you can short uniQure N-V stock.

uniQure N-V share dividends

We're not expecting uniQure N-V to pay a dividend over the next 12 months.

Have uniQure N-V's shares ever split?

uniQure N-V's shares were split on a 1:5 basis on 30 January 2014. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your uniQure N-V shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for uniQure N-V shares which in turn could have impacted uniQure N-V's share price.

uniQure N-V share price volatility

Over the last 12 months, uniQure N-V's shares have ranged in value from as little as $25.8 up to $52.19. A popular way to gauge a stock's volatility is its "beta".

QURE.US volatility(beta: 1.13)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while uniQure N-V's is 1.1307. This would suggest that uniQure N-V's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

uniQure N-V overview

uniQure N. V. , a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.

Frequently asked questions

What percentage of uniQure N-V is owned by insiders or institutions?
Currently 6.585% of uniQure N-V shares are held by insiders and 96.17% by institutions.
How many people work for uniQure N-V?
Latest data suggests 332 work at uniQure N-V.
When does the fiscal year end for uniQure N-V?
uniQure N-V's fiscal year ends in December.
Where is uniQure N-V based?
uniQure N-V's address is: Paasheuvelweg 25a, Amsterdam, Netherlands, 1105 BP
What is uniQure N-V's ISIN number?
uniQure N-V's international securities identification number is: NL0010696654
What is uniQure N-V's CUSIP number?
uniQure N-V's Committee on Uniform Securities Identification Procedures number is: N90064101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site